Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Monday, December 22, 2014

Novel Agent Counters tPA Risks

How many years before this becomes standard use?
http://www.medpagetoday.com/Cardiology/Strokes/49257
A novel agent to mitigate adverse effects of stroke thrombolytics decreased the risk of intracranial hemorrhage and improved recovery, according to top-line results from a phase II trial.
Called THR-18, the investigational drug was associated with no cases of intracranial hemorrhage found on CT imaging 2 days after being given with tissue plasminogen activator (tPA) for acute ischemic stroke in the small trial (P=0.02 versus placebo), developer D-Pharm announced.
Advertisement
The higher of the two doses of the agent tested in the trial (0.54 mg/kg) doubled the recovery rate at 30 days as assessed by either neurologic deficit measured with the NIH stroke scale score or disability in activities of daily living on the modified Rankin Scale.

More at link.
Posted by at
Labels: , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)